ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1713 • ACR Convergence 2023

    Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model

    Elisa Dalix1, Mathieu Maalouf1, Robin Caire2, Guillaume Courbon1, Virginie Dumas3, Sylvie Peyroche1, Marie-Thérèse Linossier1, Mireille Thomas1, Charles-Antoine Arthaud1, Arnaud Vanden-Bossche1 and Hubert Marotte4, 1Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, 2Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, 3Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, 4CHU Saint-Etienne, Saint-Etienne, France

    Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
  • Abstract Number: 1736 • ACR Convergence 2023

    The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis

    Patricia Riedlova1, Kieran Woolcock2, Cecilia Ansalone2 and Carl Goodyear2, 1University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Osteoclasts (OCs) are multinucleated bone-resorbing cells playing a key role in rheumatoid arthritis (RA). Under physiological conditions, OCs are in balance with bone-forming osteoblasts,…
  • Abstract Number: 1752 • ACR Convergence 2023

    Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint

    Chunyan Xiang1, Soomin Hong1, Bingjiao Zhao2, Hui Pi3, Fang Du4, Xingyu Lu5, Yuanjia Tang1, Nan Shen6, Chunxi Yang7 and Runci Wang8, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China, 3Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China, 4Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 5Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 6Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 8Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China

    Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed…
  • Abstract Number: 1768 • ACR Convergence 2023

    The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study

    Christopher Rooney1, Ian Jeffery2, Kulveer Mankia3, Mark Wilcox1 and Paul Emery4, 1University of Leeds, Leeds, United Kingdom, 24D Pharma plc, Cork, Ireland, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…
  • Abstract Number: 1867 • ACR Convergence 2023

    Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography

    Mathias Hänel1, Rasmus Klose-Jensen2, Josephine Therkildsen3, Anne-Birgitte Garm Blavnsfeldt3, Bente Langdahl3, Stinus Gadegaard Hansen4, Kresten Keller5 and Ellen Margrethe Hauge3, 1Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, 2Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Aarhus University Hospital, Aarhus, Denmark, 4Odense University Hospital, Svendborg Sygehus, Svendborg, Denmark, 5Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…
  • Abstract Number: 2021 • ACR Convergence 2023

    Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy

    Juan Ruiz1, Sheneze Madramootoo2, Maria A. Lopez-Olivo1, Namrata Singh3 and Maria Suarez-Almazor4, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3University of Washington, Bellevue, WA, 4MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…
  • Abstract Number: 2106 • ACR Convergence 2023

    Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls

    Stephen Oakley1, Samantha Stott1, Kerri Gill1, Chan Virgil1, Lyanne Weston2 and Theo de Malmanche1, 1John Hunter Hospital, New Lambton, Australia, 2Australian Red Cross Blood Service, Alexandria, Australia

    Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients…
  • Abstract Number: 2122 • ACR Convergence 2023

    Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study

    Cristina Corrales Selaya1, Nuria Vegas Revenga2, Jose Antonio Parra3, Virginia Portilla4, Ricardo Blanco5, Miguel A Gonzalez-Gay6, Ivan Ferraz Amaro7 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Galdakao- Usansolo, Galdakao, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 7Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…
  • Abstract Number: 2138 • ACR Convergence 2023

    Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis

    K Wysham1, Hannah Brubeck2, Aaron Baraff3, Punyasha Roul4, Namrata Singh5, James Andrews6, Grant Cannon7, Gary Kunkel8, Ted R Mikuls9, Bryant England4, Dolores Shoback10, Patti Katz11, Jose Garcia12, Ariela Orkaby13 and Joshua Baker14, 1VA Puget Sound/University of Washington, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3VA Puget Sound Seattle, Seattle, WA, 4University of Nebraska Medical Center, Omaha, NE, 5University of Washington, Bellevue, WA, 6University of Washington, Seattle, WA, 7University of Utah and Salt Lake City VA, Salt Lake City, UT, 8University of Utah, Salt Lake City, UT, 9Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 10San Francisco VA Medical Center, San Francisco, CA, 11University of California San Francisco, San Rafael, CA, 12VA Puget Sound Healthcare System, Seattle, WA, 13Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, 14University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Frailty occurs prematurely in RA. Levels of frailty are higher in Veteran populations than civilians1. Frailty has been shown to predict osteoporotic fractures in…
  • Abstract Number: 2154 • ACR Convergence 2023

    Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs

    Sebastian Ibanez Vodnizza1, María Paz Poblete2, María Francisca Valenzuela3, María Magdalena Canals2, Dominga García2 and Carla Jaque3, 1Clinica Alemana de Santiago / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, 2Hospital Padre Hurtado / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, 3Hospital Padre Hurtado, Santiago, Chile

    Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…
  • Abstract Number: 2171 • ACR Convergence 2023

    Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

    Yoshinobu Koyama1, Yoshiharu Sato2, Moe Tokunaga(Sakamoto)3 and Yu Nakai3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: To date, there are no head-to-head clinical trials directly comparing the effects between IL-6i and JAKi on bone destruction in RA. In recent years,…
  • Abstract Number: 2451 • ACR Convergence 2023

    TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank

    Karen Costenbader1, Zhi Yu2, Emily G. Oakes3, Michelle Robinette4, Mridul Agarwal5, Buu Truong6, Md Mesbah Uddin6, Alexander Bick7, Abhishek Niroula6, Daniel Solomon3 and Pradeep Natarajan8, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Broad Institute; Massachusetts General Hospital, Cambridge, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital; Dana-Farber Cancer Institute, Boston, MA, 5Dana-Farber Cancer Institute, Boston, MA, 6Broad Institute, Cambridge, MA, 7Broad Institute; Vanderbilt University Medical Center, Nashville, TN, 8Broad Institute; Massachusetts General Hospital, Boston, MA

    Background/Purpose: Clonal hematopoiesis (CH), the clonal expansion of somatically mutated blood cells in people without hematologic malignancy, is found in ~10% of people age ≥…
  • Abstract Number: 2541 • ACR Convergence 2023

    Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

    Joshua Baker1, James O'Dell2, Bryant England2, Jon Giles3, Jefferey Newcomb4, Michael George1, Geoffrey Thiele2, Larry Moreland5, S. Louis Bridges6, Jeffrey R Curtis7 and Ted R Mikuls8, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Columbia University, New York, NY, 4University of Nebraska, Omaha, NE, 5University of Colorado, Denver, CO, 6Hospital for Special Surgery, New York, NY, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
  • Abstract Number: 0029 • ACR Convergence 2023

    Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts

    Nozima Aripova1, Michael Duryee1, Carlos Hunter1, Breanna Butler1, Amy Nelson1, Bryant England1, James O'Dell1, Jill Poole1, Geoffrey Thiele1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease…
  • Abstract Number: 0094 • ACR Convergence 2023

    Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

    Anna Helena Jonsson1, Carlos Donado2, Erin Theisen2, Dominique Jones1, Aparna Nathan3, Fan Zhang4, Accelerating Medicines Partnership (AMP): RA/SLE1, Soumya Raychaudhuri1 and Michael Brenner2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Harvard Medical School, Boston, MA, 4University of Colorado, Aurora, CO

    Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. While most research has focused on CD4+ T cells, we have found that CD8+…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology